Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy

- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy

Liver Cirrhosis

Acute Kidney Injury

- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)

Albumin

Standard Medical Treatment

Institute of Liver & Biliary Sciences

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development - A Randomised Placebo Controlled Trial- A Pilot Study

Ascitic fluid absolute neutrophil count < 250

Institute of Liver and Biliary Sciences, India

Obesity

Weight Loss

Body Weight

Morbid Obesity

450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.
30-day post-embolization endoscopic biopsy

Left gastric artery embolization

Bariatric Embolization Trial for the Obese Nonsurgical

Safety outcomes involving the use of left gastric artery embolization

Concentration of Ghrelin-producing cells pre-embolization obtained through endoscopic biopsy and measured by cells per milliliter, will be subtracted from the concentration of Ghrelin-producing cells obtained post-embolization from endoscopic biopsy. This value will be converted into a percentage change and reported.

University of Calgary

Calgary Adult Bariatric Surgery Clinic

Peter Lougheed Center, Mayfair Diagnostics

Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.

Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)

Liver Cirrhoses

Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).

Branched chain amino acid

an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)

Placebo

Dyanand Medical College and Hospital

Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C

Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial

Change in CT Skeletal muscle index (cm2/m2) (i.e difference between the baseline and 3 month values)

3-month change in Hand Grip Strength (Kilogram) (calculated as the difference between the baseline and 3-month values obtained by Hand Grip Dynamometer)

3-month change in muscle performance assessed by change in Gait Velocity (m/min)

3-month event-free survival at 3 months (events including complications of Cirrhosis i.e. Hepatic encephalopathy, Ascites and edema, Variceal Hemorrhage, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome)

Change in health related quality of life measure by Short Form Health Survey (SF 36) QUESTIONNAIRE

esophageal and gastric varices/nausea

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development

Bariatric Embolization Trial for the Obese Nonsurgical

Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C

Il database di erbe medicinali più completo supportato dalla scienza